| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-05-23 | Ionis Pharmaceuticals (USA - CA) MD Anderson Cancer Center (USA - TX) | cancer therapeutics based on antisense technology | R&D |
Cancer - Oncology | R&D agreement | |
| 2016-05-20 | Genmab (Denmark) Janssen Biotech - J&J (USA) | bispecific antibodies using DuoBody™ technology | undisclosed | R&D |
Autoimmune diseases - Inflammatory diseases - Cancer - Oncology | Milestone |
| 2016-05-19 | Chugai Pharmaceutical (Japan) Osaka University Immunology Frontier Research Center (IFReC) (Japan) | immunology research | immunological diseases | R&D |
Immunological diseases | R&D agreement |
| 2016-05-19 | Enterome Bioscience (France) | establishment of a new subsidiary in the US |
Establishment of a new subsidiary in the US | |||
| 2016-05-18 | Thermo Fisher Scientific (USA - MA) ProBioGen (Germany) | GlymaxX® | licensing |
Allergic diseases - Diagnostic - Technology - Services | Licensing agreement | |
| 2016-05-18 | Vaximm (Germany) | nomination | Cancer - Oncology | Nomination | ||
| 2016-05-17 | Celgene (USA - NJ) Agios Pharmaceuticals (USA - MA) | AG-120 | cancers harboring an IDH1 mutation | licensing |
Cancer - Oncology | Licensing agreement |
| 2016-05-17 | BMS (USA - NY) | expansion of Devens biologics facility | opening of new premises |
Opening of new premises | ||
| 2016-05-17 | Novartis (Switzerland) | Novartis Pharmaceuticals and Novartis Oncology | restructuring nomination resignation |
Cancer - Oncology - CNS diseases - Ophtalmological diseases - Immunological disases - Respiratory diseases - Cardiovascular diseases - Dermatological diseases | Restructuring | |
| 2016-05-17 | ALK Abello (Denmark) | nomination |
Allergic diseases | Nomination | ||
| 2016-05-17 | Fate Therapeutics (USA - CA) | nomination |
Cancer - Oncology - Immunological diseases - Autoimmune diseases | Nomination | ||
| 2016-05-16 | Johns Hopkins University (USA - MD) Sanofi Genzyme (USA - MA), a Sanofi company (France) | multiple sclerosis | R&D |
Neurodegenerative diseases | R&D agreement | |
| 2016-05-16 | University of Pennsylvania (USA - PA) Biogen (USA - CA) | gene therapy and gene editing technologies | R&D collaboration |
CNS diseases, Muscular diseases, Ophtalmological diseases | R&D agreement | |
| 2016-05-16 | RegenXBiosciences (USA - MD) Biogen (USA - CA) | gene therapy product candidates based on the NAV Technology Platform | two undisclosed rare genetic vision disorders | development commercialisation licensing |
Rare diseases - Genetic diseases - Ophtalmological diseases | Licensing agreement |
| 2016-05-16 | BiolineRx (Israel) MaRS Innovation (Canada) | collaboration |
Collaboration agreement | |||
| 2016-05-12 | Oxford Biomedica (UK) | resignation |
Resignation | |||
| 2016-05-12 | Neovacs (France) Stellar Biotechnologies (USA - CA) | Neostell | joint-venture |
Technology - Services | Joint-venture agreement | |
| 2016-05-11 | The Lead Discovery Center (LDC) (Germany) Max Planck Innovation (Germany) Boehringer Ingelheim (Germany) | schizophrenia | licensing |
CNS diseases - Mental diseases | Licensing agreement | |
| 2016-05-11 | Opko Health (USA - Fl) | nomination |
Nomination | |||
| 2016-05-10 | Selvita (Poland) Pharmaceutical Research Institute (Poland) | collaboration R&D |
Technology - Services - Ophtalmological diseases | Collaboration agreement |
